BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 24583247)

  • 1. Entecavir vs. lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation.
    Chen CH; Lin CL; Hu TH; Hung CH; Tseng PL; Wang JH; Chang JY; Lu SN; Chien RN; Lee CM
    J Hepatol; 2014 Jun; 60(6):1127-34. PubMed ID: 24583247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lamivudine improves short-term outcome in hepatitis B virus-related acute-on-chronic liver failure patients with a high model for end-stage liver disease score.
    Li X; Gao F; Liu H; Zhang H; Liu Y; Ye X; Geng M; Sun L; Wang R; Li Y; Jiang Y; Wang X; Zhou G; Yang Z; Li A; Zeng H; Wang X
    Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):1-9. PubMed ID: 27749778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tenofovir, entecavir, and lamivudine in patients with severe acute exacerbation and hepatic decompensation of chronic hepatitis B.
    Park JG; Lee YR; Park SY; Lee HJ; Tak WY; Kweon YO; Jang SY; Chun JM; Han YS; Hur K; Lee HW; Kang MK
    Dig Liver Dis; 2018 Feb; 50(2):163-167. PubMed ID: 29089265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.
    Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI
    J Gastroenterol Hepatol; 2010 Aug; 25(8):1374-80. PubMed ID: 20659226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir.
    Heo NY; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ
    J Hepatol; 2010 Sep; 53(3):449-54. PubMed ID: 20646776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of plasma exchange on entecavir-treated chronic hepatitis B patients with hepatic de-compensation and acute-on-chronic liver failure.
    Yue-Meng W; Yang LH; Yang JH; Xu Y; Yang J; Song GB
    Hepatol Int; 2016 May; 10(3):462-9. PubMed ID: 26482576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone.
    Shim JH; Suh DJ; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS
    Hepatology; 2009 Oct; 50(4):1064-71. PubMed ID: 19637288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of prognosis to lamivudine in patients with spontaneous reactivation of hepatitis B virus-related acute-on-chronic liver failure: using virologic response at week 4.
    Xiang-Hui Y; Lang X; Yan Z; Li Z; Xiao-Feng S; Hong R
    Eur J Intern Med; 2014 Nov; 25(9):860-4. PubMed ID: 25439100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiviral efficacy of lamivudine versus entecavir in patients with hepatitis B virus-related advanced hepatocellular carcinoma.
    Shin HS; Kim SU; Park JY; Kim DY; Han KH; Chon CY; Baatarkhuu O; Ahn SH
    J Gastroenterol Hepatol; 2012 Sep; 27(9):1528-34. PubMed ID: 22497450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Entecavir 1.0mg monotherapy or entecavir plus adefovir dipivoxil for patients with lamivudine-resistant chronic hepatitis B had suboptimal response to lamivudine plus adefovir dipivoxil].
    Xing J; Han T; Liu L; Li Y; Li J; Li Y; Xiao SX
    Zhonghua Gan Zang Bing Za Zhi; 2011 Nov; 19(11):828-32. PubMed ID: 22433304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term entecavir versus lamivudine therapy for HBeAg-negative patients with acute-on-chronic hepatitis B liver failure.
    Lai J; Yan Y; Mai L; Zheng YB; Gan WQ; Ke WM
    Hepatobiliary Pancreat Dis Int; 2013 Apr; 12(2):154-9. PubMed ID: 23558069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Lamivudine Versus Entecavir for Treating Chronic Hepatitis B Virus-related Acute Exacerbation and Acute-on-Chronic Liver Failure: A Systematic Review and Meta-Analysis.
    Huang KW; Tam KW; Luo JC; Kuan YC
    J Clin Gastroenterol; 2017 Jul; 51(6):539-547. PubMed ID: 28067752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of lamivudine or entecavir on acute exacerbation of chronic hepatitis B.
    Kanda T; Shinozaki M; Kamezaki H; Wu S; Nakamoto S; Arai M; Fujiwara K; Goto N; Imazeki F; Yokosuka O
    Int J Med Sci; 2012; 9(1):27-32. PubMed ID: 22211086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simple scoring system predicting genotypic resistance during rescue therapy for Lamivudine-resistant chronic hepatitis B.
    Lee JH; Yoon JH; Cho EJ; Yang HJ; Jang ES; Kwak MS; Hwang SY; Yu SJ; Lee CH; Kim YJ; Kim CY; Lee HS
    J Clin Gastroenterol; 2012 Mar; 46(3):243-50. PubMed ID: 21716122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B.
    Wong VW; Wong GL; Yiu KK; Chim AM; Chu SH; Chan HY; Sung JJ; Chan HL
    J Hepatol; 2011 Feb; 54(2):236-42. PubMed ID: 21030105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of prior lamivudine use on the antiviral efficacy and development of resistance to entecavir in chronic hepatitis B patients.
    Hwang JA; Kim KB; Yang MJ; Lim SG; Hwang JC; Cheong JY; Cho SW; Kim SS
    Clin Mol Hepatol; 2015 Jun; 21(2):131-40. PubMed ID: 26157750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine.
    Bowden S; Locarnini S; Chang TT; Chao YC; Han KH; Gish RG; de Man RA; Yu M; Llamoso C; Tang H
    World J Gastroenterol; 2015 Apr; 21(15):4644-51. PubMed ID: 25914474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment response and evolution of HBV resistance during lamivudine plus adefovir or entecavir therapy in patients with adefovir-resistant mutants.
    Chen CH; Wang JH; Lu SN; Hu TH; Hung CH; Chang MH; Changchien CS; Lee CM
    Antivir Ther; 2012; 17(4):701-9. PubMed ID: 22358132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The short-term efficacy of entecavir in lamivudine-resistant chronic hepatitis B: influence of sequential adefovir-refractoriness.
    Kim JH; Kim YS; Jung YK; Kim YS; Kwon OS; Ku YS; Choi DJ; Kim JH
    Hepatogastroenterology; 2013 Jun; 60(124):842-9. PubMed ID: 23186591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adefovir-based combination therapy with entecavir or lamivudine for patients with entecavir-refractory chronic hepatitis B.
    Kim SS; Cheong JY; Lee D; Lee MH; Hong SP; Kim SO; Cho SW
    J Med Virol; 2012 Jan; 84(1):18-25. PubMed ID: 22028068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.